Watson Pharmaceuticals today announced a definitive
agreement to acquire a portfolio of generic pharmaceutical products that are
being divested as a result of the merger between Perrigo Company and Paddock
Laboratories. The portfolio consists of six products, including four
FDA-approved products and two undisclosed development-stage products. Commercialized
products in the portfolio include:
Ciclopirox shampoo 1%
Ammonium Lactate Cream 12%
Ammonium Lactate Lotion 12%
Promethazine HCl Suppositories 12.5 and 25 mg
Perrigo will supply the products to Watson under a
Manufacturing and Supply Agreement until manufacturing is transferred to Watson
or a third party. Additional details, including financial terms, have not been
disclosed.
